Myrtelle to Present Clinical Data and Regulatory Progress for MYR-101 Gene Therapy Program at ASGCT 2026

NEW YORK, May 11, 2026 /PRNewswire/ -- Myrtelle, Inc., a clinical-stage gene therapy company selected by the FDA for the START Pilot Program and focused on developing treatments for neurodegenerative diseases, today announced its participation in the upcoming American Society of Gene &...